Latest news with #IOVA


Business Insider
23-05-2025
- Health
- Business Insider
Iovance Biotherapeutics announces five-year results of Amtagvi in melanoma
Iovance Biotherapeutics (IOVA) announced five-year results from the Phase 2 C-144-01 clinical trial evaluating the individualized T cell therapy Amtagvi – lifileucel -. The C-144-01 trial investigated Amtagvi in patients with advanced melanoma previously treated with anti-PD-1 and targeted therapy, where applicable. The five-year results included meaningful overall survival – OS – results and durable responses following one-time treatment with Amtagvi. These results will be presented at the 2025 ASCO Annual Meeting. With a median follow-up of 57.8 months, patients achieved a median OS of 13.9 months, with 19.7% of patients surviving at the five-year mark. The objective response rate was 31.4%, including complete responses in 5.9% of patients and partial response in 25.5%. Among patients who responded to treatments, the median duration of response was 36.5 months. 31.3% of responders completed the five-year assessment with ongoing responses. Adverse events were consistent with known safety profiles of nonmyeloablative lymphodepletion and interleukin-2 administration. The incidence of AEs decreased rapidly within the first two weeks after Amtagvi infusion, and there were no new or late-onset treatment-related AEs.
Yahoo
23-05-2025
- Business
- Yahoo
Iovance Presents Five-Year Amtagvi Data at ASCO for Advanced Melanoma
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) presented five-year data from its Phase 2 C-144-01 trial of Amtagvi (lifileucel) during the 2025 ASCO Annual Meeting. A medical staff in white coats monitoring the progress of cancer immunotherapy trials. A five-year overall survival rate of 19.7% and a median overall survival of 13.9 months were reported in 153 patients with advanced melanoma who had previously received anti-PD-1 and targeted treatments. The intended response rate was 31.4%, with a median response duration of 36.5 months, and 5.9% complete and 25.5% partial responses. At five years, 31.3% of respondents remained active. There were no novel late-onset adverse events, and safety results were in line with established profiles of IL-2 and lymphodepletion. Amtagvi is still the only one-time T cell treatment for solid tumors that has received FDA approval. In February 2024, Amtagvi was given accelerated FDA approval for melanoma that was metastatic or unresectable following PD-1 and targeted treatments. Patients who had not responded to at least one systemic treatment were selected for the vital C-144-01 trial. Cohorts 2 and 4 of the trial followed the identical manufacturing method and regimen. Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)'s TIL platform, which targets a market where 90% of cancers are solid tumors, is the first to be approved for solid tumors. Tumor tissue is surgically removed, billions of T cells are produced in 34 days, and then the cells are infused following lymphodepletion and IL-2. Moreover, Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is assessing lifileucel in NSCLC and conducting the TILVANCE-301 Phase 3 trial in frontline melanoma. While we acknowledge the potential of IOVA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than IOVA and that has 100x upside potential, check out our report about this READ NEXT: and . Sign in to access your portfolio


Business Wire
12-05-2025
- Business
- Business Wire
Securities Fraud Investigation Into Iovance Biotherapeutics, Inc. (IOVA) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Iovance Biotherapeutics, Inc. ('Iovance' or the 'Company') (NASDAQ: IOVA) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON IOVANCE BIOTHERAPEUTICS, INC. (IOVA), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened? On May 8, 2025, Iovance released its first quarter 2025 financial results, revealing a quarterly total product revenue of $49.3 million, a significant decline from the prior quarter's $73.7 million. The Company also announced its full fiscal year 2025 total product revenue guidance had been slashed from $450 million - $475 million to $250 million - $300 million, a reduction of over 40% at the midpoint. The Company stated it was 'revising full-year 2025 revenue guidance to reflect recent launch dynamics' of the Company's T cell immunotherapy, Amtagvi ® (lifileucel). Amtagvi was commercially launched in the U.S. in the first half of 2024. On this news, Iovance's stock price fell as much as 52% during intraday trading on May 9, 2025, thereby injuring investors. Contact Us To Participate or Learn More: If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us. Charles Linehan, Esq., Glancy Prongay & Murray LLP, 1925 Century Park East, Suite 2100, Los Angeles California 90067 Email: shareholders@ Telephone: 310-201-9150 (Toll-Free: 888-773-9224) Visit our website at Follow us for updates on LinkedIn, Twitter, or Facebook. Whistleblower Notice Persons with non-public information regarding Iovance should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email shareholders@ About Glancy Prongay & Murray LLP Glancy Prongay & Murray LLP ('GPM') is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. GPM has been consistently ranked in the Top 50 Securities Class Action Settlements by ISS Securities Class Action Services. In 2018, GPM was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements. With four offices across the country, GPM's nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPM's lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPM's past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


Business Insider
12-05-2025
- Business
- Business Insider
Analysts Are Bullish on These Healthcare Stocks: Iovance Biotherapeutics (IOVA), uniQure (QURE)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Iovance Biotherapeutics (IOVA – Research Report) and uniQure (QURE – Research Report) with bullish sentiments. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. Iovance Biotherapeutics (IOVA) In a report issued on May 9, Peter Lawson from Barclays maintained a Buy rating on Iovance Biotherapeutics, with a price target of $4.00. The company's shares closed last Friday at $1.75. According to Lawson is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -10.1% and a 35.4% success rate. Lawson covers the Healthcare sector, focusing on stocks such as Springworks Therapeutics, Adaptimmune Therapeutics, and Karyopharm Therapeutics. Currently, the analyst consensus on Iovance Biotherapeutics is a Moderate Buy with an average price target of $13.83, a 612.9% upside from current levels. In a report issued on May 8, TD Cowen also maintained a Buy rating on the stock with a $5.00 price target. uniQure (QURE) Wells Fargo analyst Yanan Zhu maintained a Buy rating on uniQure on May 9 and set a price target of $30.00. The company's shares closed last Friday at $12.79. According to Zhu is ranked 0 out of 5 stars with an average return of -5.6% and a 26.4% success rate. Zhu covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Crispr Therapeutics AG. Currently, the analyst consensus on uniQure is a Strong Buy with an average price target of $36.86, representing a 203.4% upside. In a report issued on April 29, Leerink Partners also maintained a Buy rating on the stock with a $48.00 price target.